Educational Symposia
Friday, 15 September 2017

17:30 - 18:30
Room: Comandatuba 2
MANAGEMENT OF THE AUTOIMMUNE PATIENT IN LATIN AMERICA: BALANCING IMPROVED OUTCOMES AND AFFORDABILITY OF BIOLOGICS
Presented in English, Portuguese, and Spanish with simultaneous English/Portuguese/Spanish interpretation
The management of autoimmune diseases continue to improve due to the development of innovative therapies that offer patients a better benefit/risk profile. The higher acquisition cost of these therapies reflects their generally better clinical and economic value. This symposium will examine the affordability/benefit tradeoffs and propose approaches to integrate these therapies into health care practice. A panel of speakers with diverse clinical, health outcomes and policy experience in the region will explore the clinical status and economic challenges of managing autoimmune diseases in Latin America.
Moderator: Manny Papadimitropoulos, MScPhm, PhD
Lead Scientist, Lat Am-Intl HO & HTA, Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Speaker: Denizar Vianna, MD PhD
Professor, Departamento de Clinica Medica, Universidade do Estado Do Rio de Janeiro, Rio de Janeiro, Brazil
Speaker: Ingris Pelaez, MD, PhD
Rheumatologist, Hospital General de México, Mexico City, Mexico
Eli Lilly and Company
(Sponsored by Eli Lilly and Company)

18:45 - 19:45
Room: Comandatuba 2
NEW DATA SOURCES AND PARTNERSHIP OPPORTUNITIES IN BRAZIL: UNDERSTANDING MARKETS, GAPS IN CARE AND IMPROVING THE SYSTEM
Presented in English and Portuguese with simultaneous English/Portuguese interpretation
This symposium will explore a new approach for clinical and outcomes research that could be applicable in some countries of the region. The panel will discuss how a unique integrated dataset, including electronic health records (EHR), claims, costs, site of service, and physician linking, can improve understanding of the patient journey, inform HEOR studies, and improve clinical decision making and programs for patient care. From a payer’s perspective, one will learn how this comprehensive data helps to develop an understanding of gaps in care and the impact of a patient’s journey, their treatments, outcomes, and economics of care. From a health systems perspective, the discussion will focus on a use of the data to improve clinical decision criteria, patient management, and help design clinical quality programs and explore true clinical outcomes and comparative effectiveness.From an industry perspective, one will learn about how connecting to these unique data resources allows for a better understanding of market issues in treating patients in target therapeutic areas and allow HEOR and clinical researchers to better engage in real-world evidence (RWE), health system discussions, and collaboratively improve patient care.
Moderator: Stephen J. Clark
Vice President, Life Sciences, Optum, Eden Prairie, MN, USA
Speaker: Henry Sznejder, MD MBA
Director, Health Information and Planning, AMIL / United Health Group, Sao Paulo, Brazil
Speaker: Daniel Coldry, MD
Director of Clinical Systems, Amil, Rio de Janeiro, Brazil
Speaker: Bruno Scarpellini, MD, MPH
Regional RWE Manager, Latin America, Janssen Pharmaceuticals, São Paulo, Brazil
Optum
(Sponsored by Optum)
Saturday, 16 September 2017

12:30 - 13:30
Room: Comandatuba 2
ADVANCES IN GENERATING REAL-WORLD EVIDENCE IN LATIN AMERICA AND ITS VALUE FOR THE HEALTH CARE SYSTEM
Presented in English with simultaneous Spanish interpretation
Real-World Evidence (RWE) is increasingly prominent on the global stage, yet it is still in the early stages of development within the Latin American region. RWE allows pharmaceutical manufacturers, reimbursement decision makers, HTA bodies, and clinicians to better understand diseases, patient treatment, and outcomes. Compared to the USA or European markets, the current state of RWE in Latin America presents an increasing demand for decision makers and the pharmaceutical industry to find ways of developing useful and robust RWE in this region. In this symposium, an overview of the increasing need for RWE and real-world data by different stakeholders in the region will be provided with a focus on advances and methodologies that would help companies increase their generation of RWE. This includes strengthening traditional approaches, e.g. for observational studies, and aligning different health care stakeholders. The symposium will include presentations from senior representatives of HTA or regulatory bodies, the pharmaceutical industry, and QuintilesIMS.
QuintilesIMS
(Sponsored by QuintilesIMS)

13:45 - 14:45
Room: Comandatuba 2
SUSTAINABILITY OF VACCINATION PROGRAMS IN LATIN AMERICA: NEW APPROACHES AVAILABLE UNDER GOVERNMENT BUDGET RESTRICTIONS
Presented in English with simultaneous Portuguese/Spanish interpretation
The Educational Symposium will present new health economic approaches for selecting which new vaccines are introduced into a country’s vaccination program. One of the new approaches is “Portfolio Management” which is a model that defines a prioritization order for vaccine introduction based on optimization of desired health outcomes within a budget constraint, supporting decision makers at a national level. Many countries currently struggle with the introduction of new vaccines due to budget constraints. This symposium will share the rationale, concepts, and real world examples of a portfolio management model developed to define specific health and economic goals to be reached by an immunization program while working under specific constraints. It has been previously applied to support decision makers from both developed and developing countries. A second approach which will be presented at the symposium is an analysis of “Return on Investment” (ROI) associated with vaccine introduction. Sustainability of vaccine programs in Latin American countries is an important issue because the level of investment dedicated for new vaccines has been increasing in recent years. ROI analysis is especially suitable for decision makers with a financial background. It has previously been applied in different countries, and presently is being evaluated for Colombia. ROI provides information on the future government revenues and expenditures associated with vaccine introduction, which is a different and complementary approach to the typical health economic analysis. In addition, a link between the two concepts described will be analyzed and presented to the audience. These concepts can improve the sustainability of vaccination programs in the Latin America (LATAM) Region. Decision makers can utilize these methods to define specific health and economic goals, which could be achieved under specific constraints, such as current budget restrictions suffering by LATAM immunization programs. This is an excellent opportunity to share the information with the ISPOR audience of the region.
Moderator: Jorge Gomez, PhD
Health Economy Manager, GSK, Victoria, Argentina
Speaker: Baudouin Standaert, MD, PhD
Director, Health Economics, GSK, Wavre, Belgium
Speaker: Rodrigo DeAntonio, MS
Director Epidemiology and Health Outcome, GSK, Panama City, Panama
GlaxoSmithKline
(Sponsored by GlaxoSmithKline)
Sunday, 17 September 2017

12:30 - 14:30
Room: Comandatuba 2
VALUE AND PATIENT ACCESS TO SPECIALTY CARDIOVASCULAR DRUGS IN LATIN AMERICA
Presented in English, Portuguese, and Spanish with simultaneous English/Portuguese/Spanish interpretation
Although adoption of statins has reduced cardiovascular disease (CVD) mortality, cardiac, cerebrovascular, and vascular diseases remain the leading cause of death worldwide, accounting for 30% (17.3 million) of all deaths based on WHO estimates. Further, by 2030, CVD will account for about 23.6 million deaths worldwide, greatly surpassing the global burden of infectious diseases, nutritional disorders and maternal conditions combined. CVD is one of the most important public health problems of our time, accounting for the greatest expenditure in most healthcare budgets. PCSK9 inhibitors are newly developed lipid lowering therapies with a proven effect of reducing the risk of major adverse cardiovascular events. The symposium will explore how Latin American (LATAM) countries have dealt with optimizing access to innovative medicines in the recent past. It will put into context the outcomes and mortality data of recent innovative medicine to treat hypercholesterolemia with the CVD burden of illness and the economic implications. A panel of LATAM payers will discuss different approaches that could be taken to provide access to innovative products in a way that also addresses their budget constraints.
Moderator: Clifford Goodman, PhD
Senior Vice President and Director, Center for Comparative Effectiveness Research, The Lewin Group, Falls Church, VA, USA
Speaker: Luciana Ribeiro Bahia, PhD
Professor, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Speaker: José Francisco Kerr Saraiva, MD, PhD
Professor, Faculdade de Ciências Médicas, Pontifícia Universidade Católica de Campinas, Sao Paulo, Brazil
Speaker: Denizar Vianna, MD PhD
Professor, Departamento de Clinica Medica, Universidade do Estado Do Rio de Janeiro, Rio de Janeiro, Brazil
Speaker: João Paulo Reis Neto, MD
Caixa De Previdencia e Assistencia dos Servidores, Souza Marques University, Rio de Janeiro, Brazil
Speaker: César Alberto Cruz Santiago, MD, PhD
Unit Chief, Quality And Health Technologies Evaluation, Petróleos Mexicanos, PEMEX Health Services Subdirection, Mexico City, Mexico
Speaker: Diego F. Ocampo, MD
Instructor, Medicina familiar, Fundación Universitaria de Ciencias de la Salud, Bogota, Colombia
Amgen
(Sponsored by Amgen)
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.